Evidence map›Paper›PMID 18587441›Full record

ReviewBritish journal of pharmacology2008

Future innovations in anti-platelet therapies.

N E Barrett, L Holbrook, S Jones, W J Kaiser, L A Moraes, R Rana, T Sage, R G Stanley, K L Tucker, B Wright and 1 more

Open access · bronzeAbstract readReview
In one paragraph

Review in British journal of pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 1 synthesis or guideline pooled it, 150 citations in OpenAlex.

  1. Pooled it
  2. Cyclomulberrin fromRSC advances · 2026
    Article
  3. iScience · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Inhibitory Mechanisms of Lusianthridin on Human Platelet Aggregation.International journal of molecular sciences · 2021
    Article
  14. An Insight into Phytochemical, Pharmacological, and Nutritional Properties ofEvidence-based complementary and alternative medicine : eCAM · 2021
    Review
  15. Antiplatelet and Antithrombotic Effects ofEvidence-based complementary and alternative medicine : eCAM · 2021
    Article
  16. Extract fromACS omega · 2020
    Article
  17. Adaptogenic effects ofJournal of ginseng research · 2020
    Review
  18. Article
  19. Frontiers in pharmacology · 2020
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

N E BarrettSchool of Biological Sciences, University of Reading, Whiteknights, Reading, Berkshire, UK.
L Holbrook
S Jones
W J Kaiser
L A Moraes
R Rana
T Sage
R G Stanley
K L Tucker
B Wright
J M Gibbins
University of Reading · GB

Funding

Biotechnology and Biological Sciences Research CouncilBritish Heart Foundation RG/05/007/18585Medical Research Council G0400883Medical Research Council G0400883(71957)Wellcome Trust 082338
6 · The paper itself

Abstract

Platelets have long been recognized to be of central importance in haemostasis, but their participation in pathological conditions such as thrombosis, atherosclerosis and inflammation is now also well established. The platelet has therefore become a key target in therapies to combat cardiovascular disease. Anti-platelet therapies are used widely, but current approaches lack efficacy in a proportion of patients, and are associated with side effects including problem bleeding. In the last decade, substantial progress has been made in understanding the regulation of platelet function, including the characterization of new ligands, platelet-specific receptors and cell signalling pathways. It is anticipated this progress will impact positively on the future innovations towards more effective and safer anti-platelet agents. In this review, the mechanisms of platelet regulation and current anti-platelet therapies are introduced, and strong, and some more speculative, potential candidate target molecules for future anti-platelet drug development are discussed.

Indexed as

AnimalsBlood PlateletsCardiovascular DiseasesDrug DesignDrugs, InvestigationalFibrinolytic AgentsHemostasisHumansPlatelet Aggregation InhibitorsSignal TransductionThrombosisDrugs, InvestigationalFibrinolytic AgentsPlatelet Aggregation Inhibitors

Identifiers

PMID18587441
PMCPMC2451055
OpenAlexW2158070111

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.